Prosecution Insights
Last updated: July 17, 2026
Application No. 18/564,318

SCAFFOLD FOR CELL CULTURE

Non-Final OA §102§112
Filed
Nov 27, 2023
Priority
May 28, 2021 — RE 10-2021-0068884 +1 more
Examiner
BURKHART, MICHAEL D
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sea With Inc.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
516 granted / 826 resolved
+2.5% vs TC avg
Moderate +11% lift
Without
With
+11.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
38 currently pending
Career history
869
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
34.9%
-5.1% vs TC avg
§102
10.6%
-29.4% vs TC avg
§112
22.3%
-17.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 826 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claims 25-29 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should refer to other claims in the alternative only. See MPEP § 608.01(n). Accordingly, the claims have not been further treated on the merits. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 17-19, 24 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 17 recites a scaffold prepared by a method of treating seaweed with various chemical and physical extraction steps. However, the claim does not recite any actual structural elements that the claimed scaffold must comprise. It cannot be determined what, even at a minimum, structural components are in the claimed scaffold by merely reciting method steps. Although one of skill in the art could guess that certain major components of seaweed might be extracted into the scaffold, it is equally a guess as to what seaweed components are not extracted. This rejection affects all dependent claims. Claims 17 and 20 recite the limitation "the cortical layer" in line 6. There is insufficient antecedent basis for this limitation in the claims. Claims 17 and 20 recite the limitation "the medullary layer" in line 8. There is insufficient antecedent basis for this limitation in the claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 17-24 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by by Lee et al (KR 10-2151203,9/2/2020: cited by applicants as English equivalent US 20230014960 in the IDS dated 11/27/2023, reference below is to the US document). Lee et al teach a scaffold prepared from seaweed by treating seaweed with NaCl and ozone and cutting to a predetermined size (claim 4), treating the seaweed with an anionic detergent and slowly shaking to separate a cortex layer, washing a medullar layer with PBS and freeze-drying the medullar layer (claim 3). The seaweed can be G. tenax (claim 9) and the anionic detergent 1-5% (claim 5). The medullar layer may be gelled (claim 3) in CaCl2 (claim 6). Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Burkhart whose telephone number is (571)272-2915. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL D BURKHART/ Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Nov 27, 2023
Application Filed
Jan 22, 2026
Non-Final Rejection mailed — §102, §112
Apr 22, 2026
Response after Non-Final Action
Apr 22, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679881
SYNTHETIC PATHWAY ACTIVATORS
1y 2m to grant Granted Jul 14, 2026
Patent 12672643
GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF
3y 6m to grant Granted Jul 07, 2026
Patent 12655477
DNA VACCINES
4y 0m to grant Granted Jun 16, 2026
Patent 12655415
NANOCAGED ENZYMES WITH ENHANCED CATALYTIC ACTIVITY AND INCREASED STABILITY
2y 8m to grant Granted Jun 16, 2026
Patent 12637497
AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
4y 7m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
74%
With Interview (+11.1%)
3y 3m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 826 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month